Literature DB >> 17917582

A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3.

Ida Elisabeth Holm1, Elisabet Englund, Ian R A Mackenzie, Peter Johannsen, Adrian M Isaacs.   

Abstract

A large Danish family has previously been reported in which autosomal dominant frontotemporal dementia (FTD) is genetically linked to chromosome 3 (FTD-3). A mutation was recently identified in the CHMP2B gene that is probably responsible for causing disease in this family. Because of its neuropathologic findings, FTD-3 was originally categorized as a subtype of frontotemporal lobar degeneration, termed "dementia lacking distinctive histopathology." We now report a reevaluation of the neuropathologic changes in this family. Postmortem material from 4 affected family members was available for examination. Gross examination revealed generalized cortical atrophy that was most severe in frontal and temporal cortices. Microscopy showed loss of cortical neurons, microvacuolation of layer II, mild gliosis, and demyelination of the deep white matter. Results of immunohistochemical staining for alpha-synuclein, prion protein, neurofilament, and tau protein were unremarkable. Variable numbers of small, round, ubiquitin-positive cytoplasmic inclusions were present in the dentate granule layer of the hippocampus in all 4 cases. Rare ubiquitin-positive inclusions were also found in frontal and temporal cortical neurons. These inclusions were also positive for p62 but not for TDP-43. The finding of ubiquitin- and p62-positive, TDP-43-negative cytoplasmic inclusions in the hippocampus and neocortex suggests reclassification of the neuropathology of FTD-3 as a unique subtype of frontotemporal lobar degeneration with ubiquitin-positive inclusions that are TDP-43-negative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917582     DOI: 10.1097/nen.0b013e3181567f02

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  51 in total

1.  An algorithm for genetic testing of frontotemporal lobar degeneration.

Authors:  J S Goldman; R Rademakers; E D Huey; A L Boxer; R Mayeux; B L Miller; B F Boeve
Journal:  Neurology       Date:  2011-02-01       Impact factor: 9.910

Review 2.  Frontotemporal lobar degeneration: current knowledge and future challenges.

Authors:  Chiara Cerami; Elio Scarpini; Stefano F Cappa; Daniela Galimberti
Journal:  J Neurol       Date:  2012-04-25       Impact factor: 4.849

Review 3.  Update on recent molecular and genetic advances in frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

Review 4.  Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration.

Authors:  T F Gendron; K A Josephs; L Petrucelli
Journal:  Neuropathol Appl Neurobiol       Date:  2010-02-19       Impact factor: 8.090

Review 5.  Clinical aspects of familial forms of frontotemporal dementia associated with parkinsonism.

Authors:  Shinsuke Fujioka; Zbigniew K Wszolek
Journal:  J Mol Neurosci       Date:  2011-06-08       Impact factor: 3.444

Review 6.  The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Ian R A Mackenzie; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

7.  Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations.

Authors:  Hazel Urwin; Astrid Authier; Jorgen E Nielsen; Daniel Metcalf; Caroline Powell; Kristina Froud; Denise S Malcolm; Ida Holm; Peter Johannsen; Jeremy Brown; Elizabeth M C Fisher; Julie van der Zee; Marc Bruyland; Christine Van Broeckhoven; John Collinge; Sebastian Brandner; Clare Futter; Adrian M Isaacs
Journal:  Hum Mol Genet       Date:  2010-03-10       Impact factor: 6.150

8.  FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

Authors:  Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2010-05-20       Impact factor: 17.088

9.  Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases.

Authors:  A M Isaacs; C Powell; T E Webb; J M Linehan; J Collinge; S Brandner
Journal:  Neuropathol Appl Neurobiol       Date:  2008-08       Impact factor: 8.090

10.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update.

Authors:  Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2009-11-19       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.